While our analysis focused exclusively on DLBCL, it is worth noting that PD-1/PD-L1–based therapies have demonstrated distinct efficacy profiles in other malignancies, particularly solid tumors (Ferris et al., 2016; Chen et al., 2021; Xie et al., 2025). The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.